Clinical Trial Update: Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Folfoxiri plus Bev reintroduction at progression versus Folfox plus Bev followed by Folfiri plus Bev in metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOX
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: UNKNOWN